The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models

SIMPLE SUMMARY: Hyperactivation of the PI3K/AKT/mTOR cell signalling pathway is an important and well-described mechanism of trastuzumab resistance in HER2-positive breast cancer. In cell-line models of acquired trastuzumab resistance generated in our laboratory, we demonstrate this type of activati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanz-Álvarez, Marta, Martín-Aparicio, Ester, Luque, Melani, Zazo, Sandra, Martínez-Useros, Javier, Eroles, Pilar, Rovira, Ana, Albanell, Joan, Madoz-Gúrpide, Juan, Rojo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199905/
https://www.ncbi.nlm.nih.gov/pubmed/34204960
http://dx.doi.org/10.3390/cancers13112778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199905/
https://www.ncbi.nlm.nih.gov/pubmed/34204960
http://dx.doi.org/10.3390/cancers13112778

Ejemplares similares